Can-Fite BioPharma Ltd. (CANF)
After hours:
| Previous close | 1.9200 |
| Open | 2.0000 |
| Bid | 1.9100 x 1100 |
| Ask | 2.0200 x 1000 |
| Day's range | 1.9100 - 2.0100 |
| 52-week range | 1.7100 - 3.3300 |
| Volume | |
| Avg. volume | 19,984 |
| Market cap | 10.619M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
Business WireLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
PETACH TIKVA, Israel, April 25, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled "Long-term complete response to namodenoson in liver cancer with Child-Pugh B cirrhosis: A case report" (Link). The patient participated in the Phase II Liver Cancer St
Business WireCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
PETACH TIKVA, Israel, April 15, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that Biomedicines published an article titled "Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Hepatocellular Carcinoma (HCC)". Biomedicines is a highly reputable journal that publishes articles on clinical an
Business WireCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
RAMAT GAN, Israel, April 03, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company’s on
